Spots Global Cancer Trial Database for acute lymphocytic leukemia
Every month we try and update this database with for acute lymphocytic leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia | NCT00001689 | Acute Lymphocyt... Leukemia | Vincristine | - | National Institutes of Health Clinical Center (CC) | |
| Assessing the Ontogeny of P-glycoprotein Expression in Blood of Pediatric Leukemic Patients | NCT05021159 | Acute Lymphocyt... | MTX, (but the i... | 1 Month - 18 Years | Tanta University | |
| Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | NCT03263637 | Relapsed or Ref... Acute Myeloid L... Acute Lymphocyt... Chronic Lymphoc... High Risk Myelo... Chronic Myelomo... Richter's Syndr... B-cell Non-Hodg... T-cell Non-Hodg... Small Lymphocyt... Multiple Myelom... | AZD4573 | 18 Years - 130 Years | AstraZeneca | |
| WT1 for the Detection of Minimal Residual Disease | NCT00179829 | Leukemia Cancer | WT 1 Testing | - 21 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL) | NCT00500240 | Leukemia Lymphoma | Insulin Glargin... Insulin Aspart | 15 Years - | M.D. Anderson Cancer Center | |
| Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy | NCT05044039 | Non-hodgkin Lym... Acute Lymphocyt... | Duvelisib | 18 Years - | Washington University School of Medicine | |
| A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) | NCT00349596 | Acute Lymphocyt... | Decitabine | - | M.D. Anderson Cancer Center | |
| CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | NCT02819583 | Acute Lymphocyt... Chronic Lymphoc... Follicular Lymp... Mantle Cell Lym... B-cell Prolymph... Diffuse Large C... | PCAR-019 (anti-... | 18 Years - | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | |
| Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | NCT00990587 | Hematologic Mal... Acute Lymphocyt... Chronic Lymphoc... Myelodysplasia Acute Myeloid L... Chronic Myeloge... Hodgkin's Disea... | Ciclopirox Olam... | 18 Years - | University Health Network, Toronto | |
| Transfusional Iron Overload Among Leukemia Survivors | NCT01965171 | Acute Lymphocyt... Acute Myeloid L... | 5 Years - | St. Jude Children's Research Hospital | ||
| BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT | NCT02670252 | Allogeneic Hema... Busulfan Total Body Irra... Acute Lymphocyt... | Busulfan (BU) Cyclophosphamid... Total Body Irra... | 14 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies | NCT04796675 | Acute Lymphocyt... Chronic Lymphoc... Non Hodgkin's L... | Fludarabine + C... | 18 Years - | Wuhan Union Hospital, China | |
| Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS) | NCT00038805 | Leukemia | Mylotarg | 55 Years - 75 Years | M.D. Anderson Cancer Center | |
| Studies on the Significance of CXCR4-CXCL12 on Leukemic Cells Passing Through"Marrow-Blood Barrier" | NCT00155844 | Acute Myelocyti... Acute Lymphocyt... | 0 Years - | National Taiwan University Hospital | ||
| Studies on the Significance of CXCR4-CXCL12 on Leukemic Cells Passing Through"Marrow-Blood Barrier" | NCT00155844 | Acute Myelocyti... Acute Lymphocyt... | 0 Years - | National Taiwan University Hospital | ||
| Safety and Tolerability of HSC835 in Patients With Hematological Malignancies | NCT01474681 | Acute Myelocyti... Acute Lymphocyt... Chronic Myeloge... Myelodysplastic... Chronic Lymphoc... Marginal Zone L... Follicular Lymp... Large-cell Lymp... Lymphoblastic L... Burkitt's Lymph... High Grade Lymp... Mantle-cell Lym... Lymphoplasmacyt... | HSC835 | 10 Years - 55 Years | Novartis | |
| Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers | NCT00089596 | Acute Lymphocyt... Acute Myeloid L... Myelodysplastic... Non-Hodgkin Lym... Chronic Myeloge... | Expansion of um... | 12 Years - 60 Years | ViaCell | |
| Biology Studies of Hematologic Cancers | NCT00923442 | Acute Lymphobla... Myelodysplastic... Non-Hodgkins Ly... Acute Myelogeno... Hodgkins Lympho... | 1 Year - 75 Years | National Institutes of Health Clinical Center (CC) | ||
| Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant | NCT00571662 | Acute Myelogeno... Acute Lymphocyt... Chronic Myeloge... Chronic Lymphoc... Myelodysplastic... Multiple Myelom... Non-Hodgkins Ly... Hodgkins Diseas... Peripheral T-ce... | Pentostatin Total-body irra... Cyclosporine A ... Mycophenolate M... G-CSF | 19 Years - 75 Years | University of Nebraska | |
| Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia | NCT00352677 | Chronic Myeloid... Acute Lymphocyt... | INNO-406 | 18 Years - | CytRx | |
| Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | NCT02456350 | Chronic Lymphoc... Acute Lymphocyt... Lymphoma | Fludarabine Cyclophosphamid... Anti-CD19-CAR t... | 1 Year - 85 Years | Shenzhen Second People's Hospital | |
| Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy | NCT01099202 | Leukemia | Procrit (epoeti... | - | M.D. Anderson Cancer Center | |
| Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant | NCT01244906 | Hematologic Neo... | Allogeneic Hema... | 18 Years - 75 Years | Northside Hospital, Inc. | |
| Effect of Oral Supplementation With a Fibre Enriched Paediatric Sip Feed For Children With Acute Lymphocytic Leukemia | NCT01600781 | Acute Lymphocyt... | NutriniDrink/Fo... | 2 Years - 12 Years | Children's Cancer Hospital Egypt 57357 | |
| Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant | NCT01930162 | Single Umbilica... Non-myeloablati... Acute Lymphocyt... Myelodysplastic... Non-Hodgkin's L... Multiple Myelom... Chronic Lymphoc... | HSC835 | - | Novartis | |
| Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis | NCT02593123 | Hodgkin's Lymph... Lymphoid Leukem... Lymphoma Leukemia Myeloma Acute Lymphocyt... Non Hodgkin Lym... Chronic Lymphoc... Multiple Myelom... Chronic Myeloge... Myelodysplastic... Recurrent Acute... Recurrent Hodgk... Recurrent Non-H... Recurrent Plasm... Recurrent Chron... Recurrent Chron... Acute Myelogeno... | mycophenolate m... Sargramostim Filgrastim | 18 Years - 74 Years | Virginia Commonwealth University | |
| Phase l/II Study of Ruxolitinib for Acute Leukemia | NCT01251965 | Leukemia | Ruxolitinib | 14 Years - | M.D. Anderson Cancer Center | |
| Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia | NCT00313079 | Leukemia, Lymph... Leukemia Acute Lymphocyt... | MAb 216 Vincristine | 18 Years - | Stanford University | |
| Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT | NCT03066466 | Acute Myeloid L... Acute Lymphocyt... Myelodysplastic... | Atorvastatin Methotrexate Tacrolimus | 18 Years - 75 Years | Loyola University | |
| Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | NCT05170828 | Acute Leukemia Myelodysplastic... T-lymphoblastic... Acute Lymphocyt... Acute Myeloid L... Acute Biphenoty... Acute Undiffere... | Cyclophosphamid... Fludarabine Total Body Irra... Busulfan Mesna Sirolimus Mycophenolate M... Filgrastim Cyclophosphamid... Bone Marrow Tra... | 18 Years - 70 Years | Ossium Health, Inc. | |
| IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT | NCT03696537 | Acute Myeloid L... Chronic Myeloid... Acute Lymphocyt... Myelodysplastic... | Fludarabine Total Marrow Ir... | 18 Years - 65 Years | Indiana University | |
| Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) | NCT00854646 | Acute Myelocyti... Acute Lymphocyt... Chronic Myelocy... Chronic Lymphoc... Myelodysplastic... | ON 01910.Na | 18 Years - | Traws Pharma, Inc. | |
| Stem Cell Transplantation for Patients With Cancers of the Blood | NCT00467961 | CML (Chronic My... CLL (Chronic Ly... AML (Acute Myel... Acute Lymphocyt... MDS (Myelodyspl... | Miltenyi system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | NCT03076437 | Acute Lymphocyt... Chronic Lymphoc... Lymphoma | Drugs and Anti-... | 1 Year - 80 Years | Shenzhen Institute for Innovation and Translational Medicine | |
| Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) | NCT00854646 | Acute Myelocyti... Acute Lymphocyt... Chronic Myelocy... Chronic Lymphoc... Myelodysplastic... | ON 01910.Na | 18 Years - | Traws Pharma, Inc. | |
| StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies | NCT02765997 | Acute Myeloid L... Acute Lymphocyt... Chronic Myeloge... Myelodysplasia | Unmanipulated U... SR-1 UCB | 2 Years - 35 Years | Masonic Cancer Center, University of Minnesota | |
| Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation | NCT01634217 | Acute Myelogeno... Acute Lymphocyt... Chronic Myeloge... Non-Hodgkin Lym... Hodgkin Lymphom... Chronic Lymphoc... Multiple Myelom... Myelodysplastic... | iTreg | 18 Years - 75 Years | Masonic Cancer Center, University of Minnesota | |
| Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | NCT00990587 | Hematologic Mal... Acute Lymphocyt... Chronic Lymphoc... Myelodysplasia Acute Myeloid L... Chronic Myeloge... Hodgkin's Disea... | Ciclopirox Olam... | 18 Years - | University Health Network, Toronto | |
| Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer | NCT00975975 | Acute Myelogeno... Acute Lymphocyt... Chronic Myeloge... Chronic Lymphoc... Myelodysplasia Non-Hodgkin's L... Hodgkin's Disea... Multiple Myelom... Myelofibrosis Anemia, Aplasti... Hemoglobinuria,... | Basiliximab | 18 Years - | Indiana University | |
| FTS Study in Patients With Advanced Hematologic Malignancies | NCT00867230 | Myelodysplastic... Leukemia | FTS | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies | NCT03191773 | Acute Lymphocyt... Chronic Lymphoc... Lymphoma | Drugs and anti-... | 14 Years - 80 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy. | NCT00149136 | Acute Lymphocyt... | imatinib | 55 Years - 90 Years | Hospices Civils de Lyon | |
| T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies | NCT01163201 | Hematologic Mal... Acute Myeloid L... Acute Lymphocyt... Chronic Myeloge... Anemia, Refract... Chronic Myelopr... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Large Cell Non-... Lymphoblastic L... Burkitt's Lymph... High Grade Non-... | Treg cells CD3+ Teff cells Fludarabine Cyclophosphamid... Total body irra... Umbilical cord ... | 18 Years - 55 Years | Masonic Cancer Center, University of Minnesota | |
| Use Feasibility of the iThermonitor in Pediatrics Patients on Myelosuppresive Therapies | NCT02410252 | Acute Lymphocyt... Acute Myeloid L... Non-Hodgkin Lym... | iThermonitor | 2 Years - 17 Years | Massachusetts General Hospital | |
| Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy | NCT05456698 | Acute Lymphocyt... | Inotuzumab ozog... | 18 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | NCT02851589 | Acute Lymphocyt... Chronic Lymphoc... Follicular Lymp... Mantle Cell Lym... B-cell Prolymph... Diffuse Large C... | PCAR-019 (anti-... | 14 Years - | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | |
| A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia | NCT00001689 | Acute Lymphocyt... Leukemia | Vincristine | - | National Institutes of Health Clinical Center (CC) | |
| Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors | NCT00701844 | Leukemia Acute Leukemia Acute Lymphocyt... Multiple Myelom... Hematological C... Psychological D... | Writing A (Expe... Writing B (Expe... Writing C (Cont... Writing D (Cont... | 18 Years - | University of North Carolina, Chapel Hill | |
| Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide | NCT03088709 | Acute Myeloid L... Acute Lymphocyt... Myelodysplastic... Non-hodgkin Lym... Chronic Lymphoc... | Cyclophosphamid... Tacrolimus Mycophenolate m... Haploidentical ... | 16 Years - 90 Years | Loyola University | |
| Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases | NCT00038857 | Leukemia Lymphoma | Megadose of CD3... Melphalan Thiotepa Fludarabine Rabbit ATG | - 55 Years | M.D. Anderson Cancer Center | |
| A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies | NCT05201183 | Acute Myeloid L... Chronic Myeloid... Acute Lymphocyt... Myelodysplastic... | Fludarabine + T... | 18 Years - | Indiana University | |
| Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors | NCT00701844 | Leukemia Acute Leukemia Acute Lymphocyt... Multiple Myelom... Hematological C... Psychological D... | Writing A (Expe... Writing B (Expe... Writing C (Cont... Writing D (Cont... | 18 Years - | University of North Carolina, Chapel Hill | |
| Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) | NCT01167166 | Acute Myelocyti... Acute Lymphocyt... Myeloproliferat... Chronic Myeloid... | rigosertib | 18 Years - | Traws Pharma, Inc. | |
| A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) | NCT00349596 | Acute Lymphocyt... | Decitabine | - | M.D. Anderson Cancer Center | |
| Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic Syndromes | NCT01029509 | Leukemia | OPB 31121 | 18 Years - | M.D. Anderson Cancer Center | |
| CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | NCT02819583 | Acute Lymphocyt... Chronic Lymphoc... Follicular Lymp... Mantle Cell Lym... B-cell Prolymph... Diffuse Large C... | PCAR-019 (anti-... | 18 Years - | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | |
| Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia | NCT00773149 | Acute Lymphocyt... | Alemtuzumab (CA... | 15 Years - | Assistance Publique - Hôpitaux de Paris | |
| Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor | NCT01350245 | Acute Myeloid L... Myelodysplastic... Biphenotypic Le... Acute Lymphocyt... Chronic Myeloid... Chronic Lymphoc... Plasma Cell Neo... Lymphoma Hodgkin's Disea... Aplastic Anemia | Total Body Irra... Donor Lymphocyt... Cyclophosphamid... Mycophenolate M... Tacrolimus Hematopoietic s... | 18 Years - | Thomas Jefferson University | |
| Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor | NCT00304720 | Multiple Myelom... Lymphoma Acute Myelogeno... Acute Lymphocyt... Myelodysplastic... | Tacrolimus and ... | 50 Years - 70 Years | Colorado Blood Cancer Institute | |
| A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 | NCT03555955 | Hematologic Mal... Acute Myeloid L... Acute Lymphocyt... Acute Lymphobla... Myelodysplastic... | CPX-351 CPX-351 | 18 Years - | Jazz Pharmaceuticals | |
| Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML | NCT00430443 | Acute Lymphocyt... Acute Myelogeno... | Liposomal Annam... | 12 Months - 21 Years | Callisto Pharmaceuticals | |
| Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation | NCT01634217 | Acute Myelogeno... Acute Lymphocyt... Chronic Myeloge... Non-Hodgkin Lym... Hodgkin Lymphom... Chronic Lymphoc... Multiple Myelom... Myelodysplastic... | iTreg | 18 Years - 75 Years | Masonic Cancer Center, University of Minnesota | |
| Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT | NCT00516152 | Chronic Myeloid... Acute Myelogeno... Myelodysplasia Acute Lymphocyt... Severe Aplastic... Non-Hodgkin's L... Lymphoprolifera... Multiple Myelom... Advanced Myelop... | Busulfan/Fludar... | 15 Years - 61 Years | University of California, San Francisco | |
| CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia （ALL） | NCT03544021 | Leukemia, Lymph... | CART-19 cells | 14 Years - 75 Years | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | |
| A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene | NCT02141828 | Leukemia Acute Myeloid L... Acute Lymphocyt... Acute Leukemias | EPZ-5676 | 3 Months - 18 Years | Ipsen | |
| Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers | NCT00089596 | Acute Lymphocyt... Acute Myeloid L... Myelodysplastic... Non-Hodgkin Lym... Chronic Myeloge... | Expansion of um... | 12 Years - 60 Years | ViaCell | |
| Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy. | NCT00149136 | Acute Lymphocyt... | imatinib | 55 Years - 90 Years | Hospices Civils de Lyon | |
| Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | NCT03934372 | Acute Myeloid L... Accelerated Pha... Blast Phase Chr... Chronic Phase C... Acute Lymphobla... Acute Lymphocyt... Leukemia Lymphoma Solid Tumors | Ponatinib | 1 Year - 17 Years | Incyte Corporation | |
| Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning | NCT01572662 | Leukemia Acute Myeloid L... Acute Lymphocyt... Chronic Myeloid... Chronic Lymphoc... Myeloproliferat... Non-Hodgkins Ly... Hodgkins Lympho... Multiple Myelom... Myelodysplastic... | Fludarabine mon... Busulfan Stem Cell Infus... Tacrolimus Methotrexate G-CSF | 5 Years - 75 Years | M.D. Anderson Cancer Center | |
| Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia | NCT01049113 | Lymphoma Acute Lymphocyt... | ON 013105 | 18 Years - | Traws Pharma, Inc. | |
| T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies | NCT01163201 | Hematologic Mal... Acute Myeloid L... Acute Lymphocyt... Chronic Myeloge... Anemia, Refract... Chronic Myelopr... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Large Cell Non-... Lymphoblastic L... Burkitt's Lymph... High Grade Non-... | Treg cells CD3+ Teff cells Fludarabine Cyclophosphamid... Total body irra... Umbilical cord ... | 18 Years - 55 Years | Masonic Cancer Center, University of Minnesota | |
| Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood | NCT00923910 | Leukemia, Acute... Leukemia, Acute... Leukemia, Chron... Myelodysplastic... Non-Hodgkin's L... | WT1 Peptide-Pul... Donor Lymphocyt... IL-4 KLH WT1 Peptides Endotoxin Diphenhydramine Acetaminophen | 1 Year - 74 Years | National Institutes of Health Clinical Center (CC) | |
| Nonmyeloablative Allogeneic Transplant | NCT01272817 | Aplastic Anemia Paroxysmal Noct... Acute Myelogeno... Acute Lymphocyt... Myelodysplastic... Chronic Myeloge... Chronic Lymphoc... Hodgkin's Lymph... Non-Hodgkin's L... Mantle Cell Lym... Multiple Myelom... Waldenstrom Mac... Breast Cancer Renal Cell Carc... Melanoma Sarcoma Ovarian Cancer Thymoma | Nonmyeloablativ... Nonmyeloablativ... | 18 Years - 72 Years | Scripps Health | |
| Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma | NCT02043587 | Acute Lymphocyt... Adult Lymphobla... | DNR VCR PEG-asp CTX Prednisone Liposomal AraC MTX LCV AraC Etoposide Dasatinib Rituximab Hydrocortisone | 18 Years - 60 Years | University of California, San Diego | |
| Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia | NCT03840317 | Acute Lymphocyt... | Autologous CD19... | 3 Years - 65 Years | Hebei Senlang Biotechnology Inc., Ltd. | |
| A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 | NCT03555955 | Hematologic Mal... Acute Myeloid L... Acute Lymphocyt... Acute Lymphobla... Myelodysplastic... | CPX-351 CPX-351 | 18 Years - | Jazz Pharmaceuticals | |
| Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) | NCT01853631 | Non-Hodgkin Lym... Chronic Lymphoc... Acute Lymphocyt... | Dose Escalation... Expansion Phase... | - 75 Years | Baylor College of Medicine | |
| WT1 for the Detection of Minimal Residual Disease | NCT00179829 | Leukemia Cancer | WT 1 Testing | - 21 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers | NCT00089596 | Acute Lymphocyt... Acute Myeloid L... Myelodysplastic... Non-Hodgkin Lym... Chronic Myeloge... | Expansion of um... | 12 Years - 60 Years | ViaCell | |
| Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia | NCT02914977 | Acute Lymphocyt... Acute Myeloid L... | Daunorubicin | 18 Years - | University of Kansas Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
